JO3487B1 - تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به - Google Patents
تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص بهInfo
- Publication number
- JO3487B1 JO3487B1 JOP/2015/0273A JOP20150273A JO3487B1 JO 3487 B1 JO3487 B1 JO 3487B1 JO P20150273 A JOP20150273 A JO P20150273A JO 3487 B1 JO3487 B1 JO 3487B1
- Authority
- JO
- Jordan
- Prior art keywords
- copanlisib
- synthesis
- dihydrochloride salt
- intermediate compounds
- dihydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Abstract
يتعلق الاختراع الحالي بطريقة جديدة لتحضير copanlisib، وcopanlisibdihydrochloride، بمركبات وسطية جديدة، وباستخدام المركبات الوسطية الجديدة المذكورة لتحضير copanlisib المذكور.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192202.1A EP3018131A1 (en) | 2014-11-07 | 2014-11-07 | Synthesis of copanlisib and its dihydrochloride salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3487B1 true JO3487B1 (ar) | 2020-07-05 |
Family
ID=51866060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2015/0273A JO3487B1 (ar) | 2014-11-07 | 2015-11-03 | تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10035803B2 (ar) |
| EP (2) | EP3018131A1 (ar) |
| JP (1) | JP6691114B2 (ar) |
| KR (1) | KR102562286B1 (ar) |
| CN (1) | CN107074776B (ar) |
| AR (1) | AR102568A1 (ar) |
| AU (1) | AU2015341779B2 (ar) |
| BR (1) | BR112017009471B1 (ar) |
| CA (1) | CA2966796C (ar) |
| CL (1) | CL2017001130A1 (ar) |
| CO (1) | CO2017004533A2 (ar) |
| DK (1) | DK3215507T3 (ar) |
| EA (1) | EA031248B1 (ar) |
| ES (1) | ES2716730T3 (ar) |
| HR (1) | HRP20190527T8 (ar) |
| HU (1) | HUE042794T2 (ar) |
| IL (1) | IL251586B (ar) |
| JO (1) | JO3487B1 (ar) |
| LT (1) | LT3215507T (ar) |
| MX (1) | MX365111B (ar) |
| MY (1) | MY183123A (ar) |
| NZ (1) | NZ730843A (ar) |
| PE (1) | PE20170951A1 (ar) |
| PL (1) | PL3215507T3 (ar) |
| PT (1) | PT3215507T (ar) |
| RS (1) | RS58494B1 (ar) |
| SG (1) | SG11201702999XA (ar) |
| SI (1) | SI3215507T1 (ar) |
| TR (1) | TR201904346T4 (ar) |
| TW (1) | TWI697494B (ar) |
| UA (1) | UA118999C2 (ar) |
| UY (1) | UY36396A (ar) |
| WO (1) | WO2016071426A1 (ar) |
| ZA (1) | ZA201703866B (ar) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EA031493B9 (ru) | 2013-04-08 | 2019-12-18 | Байер Фарма Акциенгезельшафт | Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| AU2016231259A1 (en) | 2015-03-09 | 2017-09-21 | Bayer Healthcare Pharmaceuticals Inc. | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
| JP6935415B2 (ja) | 2016-03-08 | 2021-09-15 | バイエル ファーマ アクチエンゲゼルシャフト | ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類 |
| WO2018054782A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
| TW565582B (en) * | 2001-04-13 | 2003-12-11 | Kaneka Corp | Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them |
| ATE316085T1 (de) * | 2001-08-15 | 2006-02-15 | Du Pont | Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge |
| RU2326881C9 (ru) * | 2002-09-30 | 2009-04-10 | Байер Фармасьютикалс Корпорейшн | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009091550A2 (en) * | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| JP5466767B2 (ja) | 2009-11-04 | 2014-04-09 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
-
2014
- 2014-11-07 EP EP14192202.1A patent/EP3018131A1/en not_active Withdrawn
-
2015
- 2015-05-11 UA UAA201705431A patent/UA118999C2/uk unknown
- 2015-11-03 JO JOP/2015/0273A patent/JO3487B1/ar active
- 2015-11-05 AU AU2015341779A patent/AU2015341779B2/en active Active
- 2015-11-05 KR KR1020177011704A patent/KR102562286B1/ko active IP Right Grant
- 2015-11-05 HU HUE15790141A patent/HUE042794T2/hu unknown
- 2015-11-05 SG SG11201702999XA patent/SG11201702999XA/en unknown
- 2015-11-05 PT PT15790141T patent/PT3215507T/pt unknown
- 2015-11-05 LT LTEP15790141.4T patent/LT3215507T/lt unknown
- 2015-11-05 WO PCT/EP2015/075765 patent/WO2016071426A1/en active Application Filing
- 2015-11-05 BR BR112017009471-1A patent/BR112017009471B1/pt active IP Right Grant
- 2015-11-05 MY MYPI2017701571A patent/MY183123A/en unknown
- 2015-11-05 CA CA2966796A patent/CA2966796C/en active Active
- 2015-11-05 EP EP15790141.4A patent/EP3215507B1/en active Active
- 2015-11-05 ES ES15790141T patent/ES2716730T3/es active Active
- 2015-11-05 US US15/524,478 patent/US10035803B2/en active Active
- 2015-11-05 NZ NZ730843A patent/NZ730843A/en unknown
- 2015-11-05 TR TR2019/04346T patent/TR201904346T4/tr unknown
- 2015-11-05 PL PL15790141T patent/PL3215507T3/pl unknown
- 2015-11-05 CN CN201580059995.1A patent/CN107074776B/zh active Active
- 2015-11-05 PE PE2017000848A patent/PE20170951A1/es unknown
- 2015-11-05 RS RS20190398A patent/RS58494B1/sr unknown
- 2015-11-05 MX MX2017005891A patent/MX365111B/es active IP Right Grant
- 2015-11-05 SI SI201530660T patent/SI3215507T1/sl unknown
- 2015-11-05 EA EA201790982A patent/EA031248B1/ru not_active IP Right Cessation
- 2015-11-05 JP JP2017523873A patent/JP6691114B2/ja active Active
- 2015-11-05 DK DK15790141.4T patent/DK3215507T3/en active
- 2015-11-06 AR ARP150103617A patent/AR102568A1/es unknown
- 2015-11-06 UY UY0001036396A patent/UY36396A/es not_active Application Discontinuation
- 2015-11-06 TW TW104136727A patent/TWI697494B/zh active
-
2017
- 2017-04-05 IL IL251586A patent/IL251586B/en active IP Right Grant
- 2017-05-05 CO CONC2017/0004533A patent/CO2017004533A2/es unknown
- 2017-05-05 CL CL2017001130A patent/CL2017001130A1/es unknown
- 2017-06-06 ZA ZA2017/03866A patent/ZA201703866B/en unknown
-
2019
- 2019-03-18 HR HRP20190527TT patent/HRP20190527T8/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500833A1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| NZ765780A (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JO3487B1 (ar) | تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
| IN2014CH00247A (ar) | ||
| JOP20170100B1 (ar) | توليف مركبات إندازول | |
| MX2016012056A (es) | Procedimiento de compuesto antifungico. | |
| MX2016012053A (es) | Procedimiento de compuesto antifungico. | |
| IN2014MU00455A (ar) | ||
| MX2017011389A (es) | Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos. | |
| MX2016015624A (es) | Proceso para la preparacion de derivados de tiazol. | |
| HRP20190286T1 (hr) | Postupci za pripremu spojeva, kao što su 3-arilbutanali, korisni u sintezi medetomidina | |
| ZA201803250B (en) | New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3 | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| MX2016016398A (es) | Preparacion de piperidin-4-carbotioamida. | |
| MX2016015623A (es) | Proceso para la preparacion de derivados dihidroisoxazol. | |
| IN2014CH00444A (ar) | ||
| IN2014MU00072A (ar) | ||
| IN2013MU01501A (ar) | ||
| MX2017011388A (es) | Proceso para la preparacion de derivados de fenilisoxazolina sustituida. | |
| IN2014MU00070A (ar) | ||
| IN2014MU01191A (ar) | ||
| TW201613927A (en) | Method for preparation of substituted imidazopyridazines | |
| IN2013MU01524A (ar) |